Food and Staples Retailing
Company Overview of OptumRx, Inc.
OptumRx, Inc., doing business as Prescription Solutions by OptumRx, provides pharmacy benefit management services. It operates a network of mail service pharmacies and community pharmacies. The company also manages prescription drug benefits of commercial, Medicare, government health plans, and employers and unions. In addition, it offers specialty pharmacy and clinical programs. The company serves managed care organizations, employers, unions/Taft Hartley trust funds, and consultants. The company was founded in 1989 and is based in Irvine, California. OptumRx, Inc. operates as a subsidiary of OptumRx Holdings, LLC.
2300 Main Street
Irvine, CA 92614
Founded in 1989
Key Executives for OptumRx, Inc.
Chief Medical Officer, Vice President of Clinical Services and Senior Medical Director
Chief Medical Officer and Senior Vice President
Senior Vice President of Mail Service and Specialty Operations
Compensation as of Fiscal Year 2015.
OptumRx, Inc. Key Developments
OptumRx Announces Executive Changes
Mar 30 15
OptumRx and Catamaran Corporation announced they have agreed to combine. Upon closing, Mark Thierer, Catamaran's chairman and chief executive officer, will serve as chief executive officer of OptumRx and Timothy Wicks, the current chief executive officer of OptumRx, will become president. Jeff Park, who currently serves Catamaran as executive vice president, Operations, will become the chief operating officer for OptumRx. Jeffrey Grosklags, currently the chief financial officer of OptumRx, will continue in that role.
OptumRx Reports Earnings Results for the Third Quarter Ended September 30, 2014
Oct 16 14
OptumRx reported earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported revenues grew 27% year-over-year to $8 billion, as third quarter script volumes increased 17% year-over-year to 142 million adjusted scripts and stronger volumes in specialty pharmaceuticals increased total revenues. Earnings from operations grew 65% to $326 million.
Orexo Enters an Exclusive Reimbursement Agreement with UnitedHealth Group and OptumRx for Zubsolv
Mar 12 14
Orexo AB announced a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of ZUBSOLV. Under the agreement, ZUBSOLV will be given preferred, Tier 2 brand status on UnitedHealth Group commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid dependence through June 30, 2014. Beginning on July 1, 2014 ZUBSOLV will become the only buprenorphine/naloxone combination product on all of UnitedHealth's closed and highly managed health plan formularies, inclusive of all brand and generic formulations.
Similar Private Companies By Industry
Recent Private Companies Transactions